ThisCAR-T-22(Fundamenta Therapeutics)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameThisCAR-T-22(Fundamenta Therapeutics)
Drug Alias NameAllogeneic CAR-T targeting CD22ThisCAR-T-22
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD22
TargetsCD22
Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesFundamenta Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFundamenta Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A